651 related articles for article (PubMed ID: 22546542)
1. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease.
Sugita S; Kawazoe Y; Imai A; Yamada Y; Horie S; Mochizuki M
Arthritis Res Ther; 2012 May; 14(3):R99. PubMed ID: 22546542
[TBL] [Abstract][Full Text] [Related]
2. Role of IL-22- and TNF-α-producing Th22 cells in uveitis patients with Behcet's disease.
Sugita S; Kawazoe Y; Imai A; Kawaguchi T; Horie S; Keino H; Takahashi M; Mochizuki M
J Immunol; 2013 Jun; 190(11):5799-808. PubMed ID: 23630362
[TBL] [Abstract][Full Text] [Related]
3. Effect of Interferon alfa-2a Treatment on Adaptive and Innate Immune Systems in Patients With Behçet Disease Uveitis.
Albayrak O; Oray M; Can F; Uludag Kirimli G; Gul A; Tugal-Tutkun I; Onal S
Invest Ophthalmol Vis Sci; 2019 Jan; 60(1):52-63. PubMed ID: 30601931
[TBL] [Abstract][Full Text] [Related]
4. Induction of regulatory T cells by infliximab in Behcet's disease.
Sugita S; Yamada Y; Kaneko S; Horie S; Mochizuki M
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):476-84. PubMed ID: 20861484
[TBL] [Abstract][Full Text] [Related]
5. Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behcet's disease.
Lucherini OM; Lopalco G; Cantarini L; Emmi G; Lopalco A; Venerito V; Vitale A; Iannone F
Immunol Lett; 2018 Sep; 201():38-44. PubMed ID: 30385329
[TBL] [Abstract][Full Text] [Related]
6. Possible association of proinflammatory cytokines including IL1β and TNFα with enhanced Th17 cell differentiation in patients with Behcet's disease.
Shimizu J; Takai K; Takada E; Fujiwara N; Arimitsu N; Ueda Y; Wakisaka S; Suzuki T; Suzuki N
Clin Rheumatol; 2016 Jul; 35(7):1857-63. PubMed ID: 25972082
[TBL] [Abstract][Full Text] [Related]
7. Decreased interleukin 27 expression is associated with active uveitis in Behçet's disease.
Wang C; Tian Y; Ye Z; Kijlstra A; Zhou Y; Yang P
Arthritis Res Ther; 2014 May; 16(3):R117. PubMed ID: 24887071
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T cell levels and cytokine production in active non-infectious uveitis: in-vitro effects of pharmacological treatment.
Molins B; Mesquida M; Lee RW; Llorenç V; Pelegrín L; Adán A
Clin Exp Immunol; 2015 Mar; 179(3):529-38. PubMed ID: 25354724
[TBL] [Abstract][Full Text] [Related]
9. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.
Hohki S; Ohguro N; Haruta H; Nakai K; Terabe F; Serada S; Fujimoto M; Nomura S; Kawahata H; Kishimoto T; Naka T
Exp Eye Res; 2010 Aug; 91(2):162-70. PubMed ID: 20420831
[TBL] [Abstract][Full Text] [Related]
10. Longdan Xiegan Decoction alleviates experimental autoimmune uveitis in rats by inhibiting Notch signaling pathway activation and Th17 cell differentiation.
Yin X; Qiu Y; Li Z; Guo L; Wei H; Liu B; Zhou M; Li T; Wang L; Jiang W; Bi H; Guo D
Biomed Pharmacother; 2021 Apr; 136():111291. PubMed ID: 33493870
[TBL] [Abstract][Full Text] [Related]
11. Effect of 1,25-dihydroxyvitamin D3 on Th17 and Th1 response in patients with Behçet's disease.
Tian Y; Wang C; Ye Z; Xiao X; Kijlstra A; Yang P
Invest Ophthalmol Vis Sci; 2012 Sep; 53(10):6434-41. PubMed ID: 22918640
[TBL] [Abstract][Full Text] [Related]
12. Regulatory effects of IFN-β on the development of experimental autoimmune uveoretinitis in B10RIII mice.
Sun M; Yang Y; Yang P; Lei B; Du L; Kijlstra A
PLoS One; 2011 May; 6(5):e19870. PubMed ID: 21573074
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.
Zou J; Rudwaleit M; Brandt J; Thiel A; Braun J; Sieper J
Arthritis Rheum; 2003 Mar; 48(3):780-90. PubMed ID: 12632433
[TBL] [Abstract][Full Text] [Related]
14. Cytokine production profile in patients with Behcet's disease treated with infliximab.
Misumi M; Hagiwara E; Takeno M; Takeda Y; Inoue Y; Tsuji T; Ueda A; Nakamura S; Ohno S; Ishigatsubo Y
Cytokine; 2003 Dec; 24(5):210-8. PubMed ID: 14596817
[TBL] [Abstract][Full Text] [Related]
15. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
Tognon S; Graziani G; Marcolongo R
Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
[TBL] [Abstract][Full Text] [Related]
16. CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6.
Iwahashi C; Fujimoto M; Nomura S; Serada S; Nakai K; Ohguro N; Nishida K; Naka T
Exp Eye Res; 2015 Nov; 140():53-64. PubMed ID: 26297802
[TBL] [Abstract][Full Text] [Related]
17. Th1 responses are more susceptible to infliximab-mediated immunosuppression than Th17 responses.
Kanayama K; Nakamura K; Ogino H; Sumida Y; Ihara E; Akiho H; Takayanagi R
Dig Dis Sci; 2011 Dec; 56(12):3525-33. PubMed ID: 21678051
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells.
Bing SJ; Lyu C; Xu B; Wandu WS; Hinshaw SJ; Furumoto Y; Caspi RR; Gadina M; Gery I
Mol Vis; 2020; 26():641-651. PubMed ID: 33088168
[TBL] [Abstract][Full Text] [Related]
19. Production of interleukin-17 in Behcet's disease is inhibited by cyclosporin A.
Chi W; Yang P; Zhu X; Wang Y; Chen L; Huang X; Liu X
Mol Vis; 2010 May; 16():880-6. PubMed ID: 20508866
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of T cell-mediated inflammation in uveitis by a novel anti-CD3 antibody.
Sugita S; Shimizu J; Makabe K; Keino H; Watanabe T; Takahashi M
Arthritis Res Ther; 2017 Jul; 19(1):176. PubMed ID: 28743289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
